Capecitabine Market Expansion Supported by Shilpa Medicare’s Rapid-Dispersing Tablets

Capecitabine market, an oral chemotherapy drug classified as an anti-metabolite, is converted into fluorouracil in the body, inhibiting cancer cell DNA synthesis. It is primarily used to treat breast cancer, colorectal cancer, gastric cancer, and pancreatic cancer, offering a targeted approach to managing these malignancies. The capecitabine market is driven by the rising cancer prevalence, significant treatment advancements, and supportive FDA approvals, which enhance its adoption in oncology. The market benefits from innovations such as dispersible tablets and increasing global cancer incidence, particularly in North America and Asia-Pacific. However, challenges such as hand-foot syndrome, other side effects, and high manufacturing costs may impede growth, necessitating ongoing research to improve tolerability and accessibility.

For a detailed sample PDF brochure of the report, use a corporate email ID for a quick response: Download Sample PDF:

https://www.datamintelligence.com/download-sample/capecitabine-market?sindhuri

Market Segmentation

• By Indication: Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Others

• By Synthesis Type: Chemical-based API, Biological API, Highly Potent API (HPAPI)

• By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

• By Region: North America, Europe, Asia-Pacific, South America, Middle East & Africa

Market Share

North America holds the largest market share, driven by high cancer prevalence, with approximately 1.9 million new cancer cases reported in the US in 2023, according to the American Cancer Society, and supportive FDA approvals. The region’s advanced healthcare infrastructure and robust regulatory environment facilitate widespread adoption of capecitabine. Asia-Pacific is expected to witness the fastest growth, fueled by rising cancer cases, improving healthcare systems, and increasing access to oncology therapies, particularly in countries like India and China, where healthcare investments are accelerating.

Market Drivers

The capecitabine market is propelled by the escalating global cancer prevalence, with 1.9 million new cases and 609,820 cancer-related deaths projected in the US for 2023. Breast cancer and colorectal cancer, which together account for a significant portion of the market, drive demand due to their high incidence and capecitabine’s efficacy in treatment. Treatment advancements, such as Shilpa Medicare’s dispersible tablet (Capebel), which disperses in under 90 seconds, enhance patient convenience and compliance. FDA approvals, including the updated labeling for Xeloda in December 2022, further boost market growth by ensuring clinical relevance and safety. Strategic initiatives by pharmaceutical companies to develop supportive therapies, such as OnQuality Pharmaceuticals’ OQL036 for hand-foot syndrome, address key side effects, enhancing capecitabine’s appeal. However, side effects like diarrhea, nausea, and hand-foot syndrome, combined with high manufacturing costs, pose challenges to market expansion, particularly in cost-sensitive regions.

The increasing global burden of cancer, driven by aging populations, lifestyle factors, and improved screening, underscores the need for effective chemotherapy agents like capecitabine. Collaborative efforts between pharmaceutical firms and regulatory bodies, alongside growing investments in oncology research, further support market growth. Asia-Pacific’s rapid healthcare advancements and rising cancer awareness are key catalysts, positioning the region as a high-growth market for capecitabine.

Restraints

The capecitabine market faces several restraints. Side effects such as hand-foot syndrome, diarrhea, nausea, and fatigue can deter patient adherence and limit clinical adoption, particularly in severe cases. High manufacturing costs associated with producing capecitabine and its APIs increase treatment expenses, restricting accessibility in low- and middle-income countries. Additionally, the complexity of managing cancer treatment regimens and ensuring cost-effectiveness for healthcare systems and payers poses challenges. Limited insurance coverage in certain regions further exacerbates affordability issues, hindering widespread adoption of capecitabine.

Key Players

Prominent companies in the capecitabine market include:

• F. Hoffmann-La Roche Ltd

• Sun Pharmaceutical Industries Ltd

• Shilpa Medicare Limited

• Atom Pharma

• Global Calcium

• LGM Pharma

• Cipla Ltd

• Teva Pharmaceuticals

• Angel Biogenics Pvt Ltd

• Salvavidas Pharma

These companies drive oncology innovation through research, product development, and strategic launches, enhancing capecitabine’s role in cancer treatment.

Recent Developments

• In April 2023, OnQuality Pharmaceuticals received FDA clearance for OQL036, a prophylactic treatment for capecitabine-induced hand-foot syndrome, addressing a significant side effect and improving patient tolerability.

• In February 2021, Dr. Reddy’s Laboratories launched Capecitabine Tablets, a generic equivalent of Xeloda, approved by the USFDA for colorectal and breast cancer treatment, expanding access to affordable chemotherapy.

• Shilpa Medicare introduced Capebel, a dispersible tablet for colorectal and metastatic breast cancer, featuring rapid dispersion technology (within 90 seconds), enhancing patient convenience and market competitiveness.

Segment Analysis

The breast cancer segment holds a significant share, driven by capecitabine’s efficacy in treating triple-negative and metastatic cases, supported by increasing prescriptions and FDA clearances. Colorectal cancer also contributes substantially due to its high global incidence. By synthesis type, chemical-based APIs dominate due to established manufacturing processes, while HPAPIs are gaining traction for their potency in targeted therapies. Hospital pharmacies lead distribution channels due to their role in oncology care, with online pharmacies growing rapidly due to accessibility and convenience. North America maintains dominance with its high cancer burden and regulatory support, while Asia-Pacific accelerates through healthcare infrastructure improvements and rising cancer awareness.

COVID-19 Impact

The COVID-19 pandemic disrupted the capecitabine market in 2020, particularly impacting API manufacturing due to facility closures and supply chain challenges. Reduced access to healthcare facilities delayed cancer diagnoses and treatments, affecting capecitabine demand. However, the latter half of 2020 saw a surge in demand for oncology drugs as healthcare systems adapted, with increased focus on remote consultations and online pharmacies to ensure treatment continuity. The pandemic highlighted the need for resilient supply chains and accessible cancer care, driving long-term investments in chemotherapy production and distribution.

Conclusion

The capecitabine market is poised for steady growth, driven by rising cancer prevalence, particularly breast cancer and colorectal cancer, and treatment advancements like Shilpa Medicare’s dispersible tablet. North America leads due to its high cancer burden and FDA support, while Asia-Pacific accelerates with expanding healthcare access and oncology research. Challenges such as hand-foot syndrome, other side effects, and high manufacturing costs persist, but FDA approvals and innovative solutions like OQL036 will enhance capecitabine’s role in oncology. Ongoing research, strategic launches, and increasing global cancer incidence will solidify capecitabine as a key chemotherapy agent through 2031 and beyond.

About DataM Intelligence

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us

Company Name: DataM Intelligence 4Market Research LLP

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com